Co-Authors
This is a "connection" page, showing publications co-authored by Guohui Fan and Yeming Wang.
Connection Strength
1.664
-
Phase 2a, open-label, dose-escalating, multi-center pharmacokinetic study of favipiravir (T-705) in combination with oseltamivir in patients with severe influenza. EBioMedicine. 2020 Dec; 62:103125.
Score: 0.229
-
Comparison of severity scores for COVID-19 patients with pneumonia: a retrospective study. Eur Respir J. 2020 09; 56(3).
Score: 0.226
-
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial. Trials. 2020 May 24; 21(1):422.
Score: 0.221
-
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2020 05 16; 395(10236):1569-1578.
Score: 0.220
-
Comparative Outcomes of Adults Hospitalized With Seasonal Influenza A or B Virus Infection: Application of the 7-Category Ordinal Scale. Open Forum Infect Dis. 2019 Mar; 6(3):ofz053.
Score: 0.202
-
Cross-reactive antibody against human coronavirus OC43 spike protein correlates with disease severity in COVID-19 patients: a retrospective study. Emerg Microbes Infect. 2021 Dec; 10(1):664-676.
Score: 0.061
-
Antibody Responses and Clinical Outcomes in Adults Hospitalized With Severe Coronavirus Disease 2019 (COVID-19): A Post hoc Analysis of LOTUS China Trial. Clin Infect Dis. 2021 05 18; 72(10):e545-e551.
Score: 0.059
-
6-month consequences of COVID-19 in patients discharged from hospital: a cohort study. Lancet. 2021 01 16; 397(10270):220-232.
Score: 0.058
-
High anal swab viral load predisposes adverse clinical outcomes in severe COVID-19 patients. Emerg Microbes Infect. 2020 Dec; 9(1):2707-2714.
Score: 0.057
-
Low-to-moderate dose corticosteroids treatment in hospitalized adults with COVID-19. Clin Microbiol Infect. 2021 Jan; 27(1):112-117.
Score: 0.057
-
Respiratory viral sepsis: epidemiology, pathophysiology, diagnosis and treatment. Eur Respir Rev. 2020 Sep 30; 29(157).
Score: 0.056
-
Use of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in context of COVID-19 outbreak: a retrospective analysis. Front Med. 2020 Oct; 14(5):601-612.
Score: 0.056
-
A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020 05 07; 382(19):1787-1799.
Score: 0.055
-
Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020 03 28; 395(10229):1054-1062.
Score: 0.054
-
Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020 02 15; 395(10223):497-506.
Score: 0.054